Corvus Pharmaceuticals, Inc
863 Mitten Road, Suite 102
3 articles with Corvus Pharmaceuticals, Inc
Corvus Pharmaceuticals Announces Publication of Preclinical Results Highlighting Antitumor Activity of CPI-444 in Multiple Tumor Models both as Monotherapy and in Combination Studies
Corvus Pharmaceuticals, Inc. today announced the publication of results of preclinical studies of CPI-444 demonstrating that it induces dose dependent anti-tumor responses as a monotherapy and in combination with anti-PD-1, anti-PD-L1 and anti-CTLA-4 therapies.
Corvus Pharmaceuticals, Inc. announced financial results for the second quarter ended June 30, 2018, and provided a business update.
Corvus Pharmaceuticals Announces Publication of Preclinical Study Results Demonstrating CPI-444 Antitumor Activity as Monotherapy
Corvus Pharmaceuticals, Inc. announced publication of results of preclinical studies of CPI-444